McMillan Office’s Amgen AMGN Stock Holding History

McMillan Office’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2M	Hold	5,530	–	–	0.23%	55
2026 Q1	$1.95M	Hold	5,530	–	–	0.25%	54
2025 Q4	$1.81M	Buy	+5,530	New	+$1.75M	0.22%	58

Other funds holding AMGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

McMillan Office's AMGN Position: Q2 2026 in Review

McMillan Office held its Amgen (AMGN) position steady in Q2 2026 at 5,530 shares worth $2M. The position accounts for 0.23% of the portfolio, ranked #55.

McMillan Office first reported a position in AMGN in Q4 2025 and has held it in 3 quarters since. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

McMillan Office held 5,530 shares of Amgen worth $2M as of Q2 2026.
McMillan Office left its Amgen share count unchanged in Q2 2026.
Amgen made up 0.23% of McMillan Office's portfolio in Q2 2026, its #55 holding.
McMillan Office first reported a position in Amgen in Q4 2025 and has held it in 3 quarters since.
3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on McMillan Office's 13F filing for Q2 2026, filed 13 Aug 2026.